Medications

Gilead buys US pharma rival Pharmasset

US biotech firm Gilead Sciences announced plans Monday to acquire rival Pharmasset, a group specializing in treatments for AIDS and hepatitis, for $11 billion.

Diseases, Conditions, Syndromes

More doubt on virus, chronic fatigue connection

A study supported by the U.S. Department of Health and Human Services could not validate or confirm previous research findings that suggested the presence of one of several viruses in blood samples of people living with chronic ...

page 3 from 3